iTeos Therapeutics anticipates this year an interim readout from its Phase III GALAXIES Lung-301 trial of its anti-TIGIT antibody belrestotug in combination with GlaxoSmithKline's anti-PD-1 monoclonal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback